Research Analysts’ updated eps estimates for Sunday, September 10th:

Antares Pharma (NASDAQ:ATRS) had its buy rating reissued by analysts at HC Wainwright. They currently have a $5.00 price target on the stock.

Activision Blizzard (NASDAQ:ATVI) had its buy rating reissued by analysts at Stifel Nicolaus.

HC Wainwright assumed coverage on shares of BioDelivery Sciences International (NASDAQ:BDSI). HC Wainwright issued a buy rating and a $5.00 price target on the stock.

Buckeye Partners L.P. (NYSE:BPL) had its buy rating reiterated by analysts at Stifel Nicolaus. Stifel Nicolaus currently has a $69.00 price target on the stock.

Peabody Energy Corporation (NYSE:BTU) had its hold rating reaffirmed by analysts at Stifel Nicolaus. Stifel Nicolaus currently has a $32.00 target price on the stock.

Salesforce.com (NYSE:CRM) had its buy rating reaffirmed by analysts at Northland Securities.

Emerge Energy Services (NYSE:EMES) had its buy rating reaffirmed by analysts at Stifel Nicolaus. The firm currently has a $13.00 price target on the stock.

FuelCell Energy (NASDAQ:FCEL) had its buy rating reissued by analysts at Cowen and Company. They currently have a $2.50 target price on the stock.

Kayne Anderson Energy Development (NYSE:KED) had its buy rating reiterated by analysts at Stifel Nicolaus. The firm currently has a $20.00 target price on the stock.

LG Display Co. (NYSE:LPL) had its buy rating reissued by analysts at Cowen and Company. They currently have a $20.40 target price on the stock.

Altria Group (NYSE:MO) had its hold rating reissued by analysts at Cowen and Company.

Maxwell Technologies (NASDAQ:MXWL) had its buy rating reissued by analysts at Cowen and Company. They currently have a $8.00 target price on the stock.

Paylocity Holding Corporation (NASDAQ:PCTY) had its buy rating reiterated by analysts at Northland Securities. The firm currently has a $55.00 price target on the stock.

Thermo Fisher Scientific (NYSE:TMO) had its buy rating reissued by analysts at Cowen and Company.

Viper Energy Partners (NASDAQ:VNOM) had its buy rating reaffirmed by analysts at Stifel Nicolaus. The firm currently has a $20.00 target price on the stock.

Receive News & Ratings for Antares Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.